Jan 15, 2020 / 04:00PM GMT
Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst
Good morning everyone. I'm happy to introduce our first medical device company of today. I'm Robbie Marcus, med-tech analyst at JPMorgan.
Very happy to introduce Tom Burns, CEO of Glaukos.
Thomas William Burns - Glaukos Corporation - CEO, President & Director
Good morning. Our mission at Glaukos from our inception has been to transform glaucoma therapy. But our vision has always been broader and more aspirational. And over the last several years, we've been building the foundation to create the next formidable, comprehensive eye care company in ophthalmology. We are building a world-class ophthalmic company, and we've accomplished quite a bit since our IPO in 2015. As you can see, from a revenue standpoint, we've grown the business nearly 40% year-on-year over the planning period. We've increased our gross margins from the mid-70s to the mid-80s, and we've funded a number of organic programs. And in doing so, we've been able to generate positive cash flow and create a
Glaukos Corp at JPMorgan Healthcare Conference Transcript
Feb 10, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers